Venrock Healthcare Capital Partners III L.P. 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:09 pm Sale |
2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Venrock Healthcare Capital Partners III L.P. | 2,952,371 6.400% |
-1,447,629 (-32.90%) |
Filing |
| 2024-02-14 8:51 pm Purchase |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Venrock Healthcare Capital Partners III L.P. | 4,400,000 8.900% |
1,512,483 (+52.38%) |
Filing |
| 2023-05-15 4:17 pm Purchase |
2023-05-05 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Venrock Healthcare Capital Partners III L.P. | 2,887,517 8.700% |
2,887,517 (New Position) |
Filing |